PSNL Earnings Prediction
The chart below shows how PSNL performed 10 days before and after its earnings report, based on data from the past quarters. Typically, PSNL sees a +0.67% change in stock price 10 days leading up to the earnings, and a +16.08% change 10 days following the report. On the earnings day itself, the stock moves by -0.53%. This data can give you a slight idea of what to expect for the next quarter's release.
PSNL Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
25.71M
40.89%
13.86%
Gross Margin
34.02%
78.30%
-4.41%
Operating Margin
-55.94%
-59.54%
-25.22%
Net Margin
-152.04%
-4.66%
168.15%
EPS
-0.64
-6.67%
166.67%
No Data Available
PSNL Earnings Analysis
Personalis, Inc. Common Stock Corporation (PSNL.O) Earnings Conference Call
Positive
Quarterly Revenue Increase: Total company revenue for the third quarter of 2024 was $25.7 million, representing a 41% increase compared with $18.2 million for the same period of the prior year.
Revenue Increase Drivers: The increase in revenue was driven by higher volume from biopharma customers and the VA MVP, which was partially offset by the expected decline from Natera.
Biopharma Revenue Surge: Biopharma revenue grew 96% compared with the same period last year, and the growth was primarily driven from higher ImmunoID Next volume from Moderna's PCV projects.
Revenue Guidance Increase: Our strong Q3 revenue also helped us to increase our guidance for the fully year, and we now expect revenue in the range of $83 million to $84 million.
Gross Margin Expansion: Gross margin expanded to 34% in the third quarter compared with 19.1% for the same period of the prior year.
Negative
Quarterly Revenue Increase: Total company revenue for the third quarter of 2024 was $25.7 million, representing a 41% increase compared with $18.2 million for the same period of the prior year.
Quarterly Net Loss Comparison: The third quarter net loss was $39.1 million compared with $29.1 million for the same period of the prior year.
Operating Expenses Decrease: Operating expenses were $23.1 million in the third quarter compared with $34.3 million for the same period of the prior year.
R&D Expense Comparison: R&D expense was $11.7 million in the second quarter compared with $16.7 million for the same period last year.
Non-Cash Expense Impact: The third quarter included a $26 million non-cash expense related to fair value accounting for the warrants exercised by Tempus.
PSNL FAQs
How does PSNL typically perform around its earnings report dates?
Is Personalis, Inc. (PSNL) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
PSNL Earning Call Sentiment
Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
PSNL.O
-5.36%Positive
The earnings call highlights strong financial performance with a 41% revenue increase and significant gross margin expansion. The partnership with Tempus and increased revenue guidance are positive indicators. Although there are concerns about net loss and lack of specific guidance for 2025, the optimistic outlook and strategic focus on MRD testing suggest potential growth. The market's reaction is likely to be positive over the next two weeks.
